Antibiotics: From Mechanism of Action to Resistance and Beyond

Indian Journal of Microbiology, Journal Year: 2024, Volume and Issue: 64(3), P. 821 - 845

Published: April 29, 2024

Language: Английский

---

Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(13), P. 11022 - 11022

Published: July 3, 2023

There are currently no pharmacological treatments available that completely halt or reverse the progression of Parkinson’s Disease (PD). Hence, there is an unmet need for neuroprotective therapies. Lewy bodies a neuropathological hallmark PD and contain aggregated α-synuclein (α-syn) which thought to be neurotoxic therefore suitable target therapeutic interventions. To investigate this further, systematic review was undertaken evaluate whether anti-α-syn therapies effective at preventing in preclinical vivo models via current human clinical trials. An electronic literature search performed using MEDLINE EMBASE (Ovid), PubMed, Web Science Core Collection, Cochrane databases collate evidence investigated targeting α-syn. Novel therapeutics provided significant reduction α-syn aggregations. Biochemical immunohistochemical analysis rodent brain tissue demonstrated reduced α-syn-associated pathology rescued dopaminergic neuronal loss. Some studies did not provide endpoints since they had yet been completed were terminated before completion. Completed trials displayed tolerability efficacy reducing patients with minimal adverse effects. Collectively, highlights capacity reduce accumulation both potential optimism further restrict loss and/or prophylactic protection avoid onset α-syn-induced PD.

Language: Английский

---

Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies

Medicinal Research Reviews, Journal Year: 2024, Volume and Issue: 44(5), P. 2078 - 2111

Published: March 26, 2024

Abstract As the world population ages, there will be an increasing need for effective therapies aging‐associated neurodegenerative disorders, which remain untreatable. Dementia due to Alzheimer's disease (AD) is one of leading neurological diseases in aging population. Current therapeutic approaches treat this disorder are solely symptomatic, making new molecular entities acting on causes extremely urgent. One potential solutions use compounds that already market. The structures have known pharmacokinetics, pharmacodynamics, toxicity profiles, and patient data available several countries. Several drugs been used successfully different from their original purposes, such as autoimmunity peripheral inflammation. Herein, we divulge repurposing area diseases, focusing antineoplastics dementia AD dementia. We briefly touch upon shared pathological mechanism between cancer drug strategies, with a focus artificial intelligence. Next, bring out current status research development drugs, provide supporting evidence retrospective, clinical, preclinical studies antineoplastic use, areas, prion‐like spreading pathologies treating AD.

Language: Английский

---

An Open‐Label, Non‐randomized, Drug‐Repurposing Study to Explore the Clinical Effects of Angiotensin II Type 1 (AT1) Receptor Antagonists on Anxiety and Depression in Parkinson's Disease

Movement Disorders Clinical Practice, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

Abstract Background The cerebral Renin‐Angiotensin System might have a role in anxiety and depression development. Objective We explored the effects of Angiotensin II Type 1 receptor blockers (ARBs) angiotensin‐converting enzyme inhibitors (ACE‐Is) on Parkinson's Disease (PD). Methods Four hundred twenty‐three newly diagnosed drug‐naïve PD patients were evaluated using State–Trait Anxiety Inventory (STAI) Geriatric Depression Scale (GDS‐15) tests monitored at baseline for up to 3 years. Results Twelve treated with ARBs 42 ACE‐Is. ARB‐treated had lower STAI scores than those ACE‐Is or drug‐free (17.2 ± 1.3 vs. 21.3 1.3, 23.8 0.5, respectively, P = 0.021) during follow‐up ( < 0.01). unaffected by any drugs throughout study. Conclusion This small sample displayed levels anxiety. Randomized clinical trials are warranted.

Language: Английский

---

Gut microbiota and Parkinson’s Disease: a new frontier in understanding neurological health

Inflammopharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Language: Английский

---

From past to future: Digital approaches to success of clinical drug trials for Parkinson's disease

Journal of Parkinson s Disease, Journal Year: 2025, Volume and Issue: unknown

Published: April 27, 2025

Recent years have seen successes in symptomatic drugs for Parkinson's disease, but the development of treatments stopping disease progression continues to fail clinical drug trials, largely due lack efficacy drugs. This may be related limited understanding mechanisms, data heterogeneity, poor target screening and candidate selection, challenges determining optimal dosage levels, reliance on animal models, insufficient patient participation, adherence trials. Most recent applications digital health technologies artificial intelligence (AI)-based tools focused mainly stages before used AI-based algorithms or models discover novel targets, inhibitors indications, recommend candidates dosage, promote remote collection. paper reviews state literature highlights strengths limitations approaches discovery from 2021 2024, offers recommendations future research practice success

Language: Английский

---

Synergistic combination of carvedilol, amlodipine, amitriptyline, and antibiotics as an alternative treatment approach for the susceptible and multidrug-resistant A. baumannii infections via drug repurposing

European Journal of Clinical Microbiology & Infectious Diseases, Journal Year: 2023, Volume and Issue: 42(9), P. 1063 - 1072

Published: July 10, 2023

Language: Английский

---

Synergizing drug repurposing and target identification for neurodegenerative diseases

Progress in molecular biology and translational science, Journal Year: 2024, Volume and Issue: unknown, P. 111 - 169

Published: Jan. 1, 2024

Language: Английский

---

Influence of sleep quality, excessive daytime sleepiness, circadian features and motor subtypes on depressive symptoms in Parkinson’s disease

Sleep Medicine, Journal Year: 2024, Volume and Issue: 125, P. 57 - 64

Published: Nov. 15, 2024

Language: Английский

---

Some Aspects and Convergence of Human and Veterinary Drug Repositioning

Molecules, Journal Year: 2024, Volume and Issue: 29(18), P. 4475 - 4475

Published: Sept. 20, 2024

Drug innovation traditionally follows a de novo approach with new molecules through complex preclinical and clinical pathway. In addition to this strategy, drug repositioning has also become an important complementary approach, which can be shorter, cheaper, less risky. This review provides overview of in both human veterinary medicine, focus on repositioning. The evolution the effectiveness are presented, including growing role data science computational modeling methods identifying drugs potential for Certain business aspects innovation, especially relevant factors market exclusivity, discussed. Despite promising it remains underutilized, applications. To change landscape mutual benefits further exploitation potency is necessary closer cooperation between all stakeholders, academia, industry, pharmaceutical authorities, policy makers, integration into unified space. For purpose, establishment conceptually “One Health Repositioning Platform” proposed. Oncology one disease areas where platform significantly support development dog (or other companion animals) anticancer therapies. As example utilization repositioning, use COX inhibitors treat cancers reviewed.

Language: Английский

---